Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers

Research output: Contribution to journalArticlepeer-review

32 Downloads (Pure)

Abstract

Background
Severe infections of the respiratory tracts of critically ill patients are common and associated with excess morbidity and mortality. Piperacillin is commonly used to treat pulmonary infections in critically ill patients. Adequate antibiotic concentration in the epithelial lining fluid (ELF) of the lung is essential for successful treatment of pulmonary infection.

Objectives
To compare piperacillin pharmacokinetics/pharmacodynamics in the serum and ELF of healthy volunteers and critically ill patients.

Methods
Piperacillin concentrations in the serum and ELF of healthy volunteers and critically ill patients were compared using population methodologies.

Results
Median piperacillin exposure was significantly higher in the serum and the ELF of critically ill patients compared with healthy volunteers. The IQR for serum piperacillin exposure in critically ill patients was six times greater than for healthy volunteers. The IQR for piperacillin exposure in the ELF of critically ill patients was four times greater than for healthy volunteers. The median pulmonary piperacillin penetration ratio was 0.31 in healthy volunteers and 0.54 in critically ill patients.

Conclusions
Greater variability in serum and ELF piperacillin concentrations is observed in critically ill patients compared with healthy adult subjects and must be considered in the development of dosage regimens. Pulmonary penetration of antimicrobial agents should be studied in critically ill patients, as well as healthy volunteers, during drug development to ensure appropriate dosing of patients with pneumonia.
Original languageEnglish
Pages (from-to)1340-1347
JournalJournal of Antimicrobial Chemotherapy
Volume73
Issue number5
Early online date29 Jan 2018
DOIs
Publication statusPublished - 1 May 2018

Fingerprint

Dive into the research topics of 'Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers'. Together they form a unique fingerprint.

Cite this